Author

M. Emirik

h-index 17 View on Semantic Scholar

We have 3 of 60 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Design, Synthesis, and Anticancer Evaluation of Novel Chalcone Derivatives Bearing Piperazine and Morpholine Moieties.

Cancer remains one of the leading causes of mortality worldwide, highlighting the need for novel anticancer agents with improved efficacy and selectivity. In this study, a series of chalcone derivatives bearing phenylpiperazine, 2-fluorophenylpiperazine, and morpholine moieties (1a-g, 2a-g, and 3a-g) were designed, syn...

N. Çalışkan, F. Yılmaz, O. E. Eyupoğlu et al. · Archiv der Pharmazie · 0 citations

Open access Aug 2026

Trifluoromethyl-Benzimidazole-Hydrazone Derivatives as Promising Selective Anticancer Agents: Synthesis, Cytotoxicity, and Molecular Docking Insights

Compound 7 represents a selective, mid-micromolar benzimidazole-hydrazone lead against MCF-7 breast cancer cells, and its predicted molecular interactions warrant further target-based, mechanistic, pharmacokinetic, and in vivo evaluation.

M. Özil, Eyüp Önelge, M. Emirik et al. · Pharmaceuticals · 0 citations

Aug 2026

Glycine-conjugated coumarin-quinazoline hybrids as potent anticancer agents: synthesis, cytotoxicity, SAR and molecular docking studies.

G glycine conjugation of a coumarin-quinazoline hybrid has not been reported previously, and the results identify it as a substituent- and cell-line-dependent strategy for improving anticancer potency and selectivity.

N. Çalışkan, M. Emirik, F. Yılmaz et al. · Bioorganic chemistry (Print) · 2 citations